Published in Obesity and Diabetes Week, June 5th, 2006
The increase is primarily due to the growth in revenues arising from worldwide Tarceva (erlotinib) sales, and Macugen (pegaptanib sodium injection)-related revenue streams. Total worldwide net sales of Tarceva for the first quarter of 2006 were $133 million. Total U.S. Macugen sales were $51 million for the first quarter of 2006.
The company reported a net loss of $17.9 million (or $0.31...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.